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Background: It has been demonstrated that myeloid-derived
suppressor cells (MDSC) are expanded in HIV-1–infected in-
dividuals and correlated with disease progression. The phase of HIV
infection during which MDSC expansion occurs, and the mechanisms
that regulate this expansion remain to be established. In this study, we
evaluated the frequency of MDSC in patients during primary HIV
infection (PHI) and factors involved in MDSC control.
Methods: Patients with PHI and chronic HIV infection (CHI) were
enrolled. PHI staging was performed according to Fiebig classification,
and circulating MDSC frequency and function were evaluated by flow
cytometry. Cytokine levels were evaluated by Luminex technology.
Results: We found that granulocytic MDSC (Gr-MDSC) frequency
was higher in patients with PHI compared with healthy donors, but
lower than that in patients with CHI. Interestingly, Gr-MDSC
expansion was observed in the early phases of HIV infection (Fiebig
II/III), but it was not associated with HIV viral load and CD4 T-cell
count. Interestingly, in PHI, Gr-MDSC frequency was inversely
correlated with plasmatic level of tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL), although a direct correlation
was observed in CHI. Furthermore, lower level of Granulocyte
Macrophage Colony Stimulating Factor (GM-CSF) was observed in
PHI compared with that in CHI. In vitro experiments demonstrated
that, differently from CHI, recombinant TRAIL–induced apoptosis
of Gr-MDSC from PHI, an effect that can be abrogated by GM-CSF.
Conclusion: We found that Gr-MDSC are expanded early during
PHI and may be regulated by TRAIL and GM-CSF levels. These
findings shed light on the fine mechanisms regulating the immune
system during HIV infection and open new perspectives for immune-
based strategies.
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INTRODUCTION
HIV-1 infection causes profound immune suppression
leading to progressive destruction of the immune system in
patients who are untreated. Recently, a subset of myeloid
cells, known as myeloid-derived suppressor cells (MDSC),
was found to be able to negatively regulate immune
functions.1–4
MDSC are a heterogenous group of immature and
highly differentiated elements belonging to the myeloid
lineage, undergoing expansion during pathologic conditions
and are characterized by a strong immune suppressive
capability.3,5–7 In humans, the identification of MDSC is
not easy because of the lack of specific markers. Moreover, at
present, a consensus regarding the combination of markers
used to identify MDSC is still lacking. However, in purified
peripheral blood mononuclear cells (PBMC), MDSC are
identified as HLA-DR-/low/CD11b++/CD33+/CD124+ and
can be divided into 2 main subsets: monocytic MDSC
(M-MDSC) and granulocytic MDSC (Gr-MDSC).8 The mono-
cytic subset contains CD14+ cells, whereas the granulocytic
subset contains CD14-/CD15+ cells.8 Another MDSC subset
HLA-DR-/low/CD11b+/CD33+/CD15+/CD162 has been char-
acterized as immature MDSC or promyelocytic MDSC that
differs from Gr-MDSC for morphological features and the
expression of CD16.9,10 Suppressive functions are mediated
through combination of several major molecular pathways,
including inducible nitric oxide synthetase (iNOS), arginase-1
(Arg-1), nicotinamide adenine dinucleotide phosphate oxidase
(NOX2), and Transforming growth factor beta.11–13 MDSC
were initially described as bone marrow suppressor cells in
mice with metastatic lung tumors,14 and there has been
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increasing interest in their role in cancer immune regulation,15
autoimmune disorders,16 and some infectious diseases.17–19
Recently, we and others showed that MDSC are
expanded in HIV-1–infected individuals and their frequency
correlates with disease progression.20–22 Although the
immunosuppressive ability of MDSC may be beneficial in
curbing the damaging effects of persistent immune activation
associated with disease progression, a deleterious effect of
MDSC has been shown as they also inhibit HIV-1–specific
CD8 T-cell response. To date, the phase of HIV infection
during which MDSC expansion occurs remains to be estab-
lished, and no data are available regarding MDSC during
primary HIV infection (PHI).
In this study, we evaluated the frequency and the
suppressive function of MDSC in patients during the acute
phase of HIV infection and investigated the possible mech-
anism driving their expansion.
METHODS
Study Population
Patients with PHI (n = 51) were enrolled at the National
Institute for Infectious Diseases (INMI) “Lazzaro Spallanza-
ni” (Rome, Italy). Patients with chronic HIV infection (CHI,
n = 26) and healthy donors (HD, n = 16) were included as
controls. All HIV-positive individuals were naive to antire-
troviral therapy. Patients with PHI were grouped according to
Fiebig classification23 as follows: II/III, IV, V, and VI.
Patients with Fiebig stage VI were defined as patients
sampled within 1 year from seroconversion. Patients with
CHI were defined as patients sampled after more than 1 year
from seroconversion. General characteristics are summarized
in Table 1. The procedures followed were in accordance with
the ethical standards of the Helsinki Declaration. The study
was approved by the Institutional Review Board of the
National Institute for Infectious Diseases (INMI) “Lazzaro
Spallanzani” (ALPHA and SIREA studies), and signed
written informed consent was obtained from all patients.
PBMC Separation and Flow Cytometry
PBMC were isolated from peripheral blood by density-
gradient centrifugation (Lympholyte-H; Cederlane). After sep-
aration, PBMC were resuspended in RPMI 1640 (EuroClone)
supplemented with 10% heat-inactivated fetal bovine serum
(EuroClone), 2 mmol/L L-glutamine, 10 mmol/L HEPES
buffer (N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid),
2 mmol/L penicillin, and 50 mg/mL streptomycin (EuroClone).
Evaluation of MDSC percentage was accomplished with 0.5 ·
106 PBMC stained with anti-Cluster of Differentiation (CD) 15,
anti-CD33, anti-Human Leucocyte Antigen-DR (HLA-DR),
anti-CD3, anti-CD56, anti-CD19, anti-CD14, anti-CD11b,
anti-CD16 (BD Biosciences), and anti-CD124 monoclonal
antibodies (mAbs) (R&D system). CD38 evaluation on T cells
was performed using anti-CD3, anti-CD8, and anti-CD38 mAbs
(BD Biosciences). Intracellular flow cytometry was performed
by using anti-CD3, anti-CD8, and anti-Interferon (IFN)-g mAbs
(BD Biosciences). Acquisition of 100,000 events was performed
in the leukocyte-gated population on FACS CANTO II and
analyzed with FACS DIVA software (BD Biosciences).
Gr-MDSC Purification and Cell Cultures
Gr-MDSC purification was performed using magnetic
selection. Briefly, PBMC from PHI were stained with anti-
CD15 FITC–conjugated mAb (BD Biosciences). After
washing, cells were labeled with anti-FITC microbeads
according to manufacturer’s instructions (Miltenyi Biotec).
The purity of sorted Gr-MDSC was .95%, as verified by
flow cytometry (data not shown). To evaluate MDSC immune
suppressive ability, Carboxy Fluorescein Diacetate Succimidyl
Ester (CFDA-SE)–labeled PBMC from HD were cultured with
purified Gr-MDSC at 1:1 ratio and stimulated with anti-CD3
(0.1 mg/mL, eBiosciences) and anti-CD28 (1 mg/mL, BD
Biosciences). Cells were maintained at 37°C in humidified air
with 5% CO2. After 5 days, lymphocyte proliferation was
evaluated by flow cytometry. HIV-specific CD8 T-cell
response was obtained by stimulating PBMC with a pool of
Gag-, Nef-, and Tat-derived peptide (1 mg/mL, National
Institutes of Health) for 18 hours. The production of IFN-g
was evaluated by flow cytometry. Gr-MDSC apoptosis was
evaluated by flow cytometry analyzing Annexin V-positive
cells (Annexin V-FITC Apoptosis Detection kit, Bender
MedSysytems). Briefly, cells were treated with recombinant
tumor necrosis factor–related apoptosis-inducing ligand (r-
TRAIL 100 ng/mL, Gibco, Life technology) and with
Granulocyte Macrophage Colony Stimulating Factor (GM-
CSF) where indicated (100 ng/mL, Peprotech). The control
condition was performed by adding water with 0.1% bovine
serum albumin (the buffer recommended by the manufacturer
to reconstitute r-TRAIL). A not-treated condition was also used
TABLE 1. Patient Characteristics
HD
PHI
CHIFiebig II/III Fiebig IV Fiebig V Fiebig VI
No. individuals 16 13 11 10 17 26
Age in years, median (IQR) 42 (31–48) 38 (32–42) 39 (32–45) 33 (28–39) 26 (23–36) 36 (31–42)
Male sex, % 8 (50) 12 (92.3) 10 (90.9) 10 (100) 16 (94.1) 21 (80.8)
CD4 T cells/mL, median (IQR) na 536 (342–659) 557 (405–663) 762 (532–1036) 648 (522–841) 450 (149–644)
Plasma HIV RNA copies/mL (Log), median (IQR) na 6.1 (5.7–7) 5.7 (4.9–6.5) 5.1 (4.3–6) 4.4 (3.7–5.2) 4.8 (4.6–5.3)
na, not applicable; IQR, interquartile range.
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(data not shown) to confirm that water with 0.1% bovine serum
albumin did not affect MDSC survival in vitro. After 18 hours,
the percentage of Annexin V-positive Gr-MDSC was analyzed.
Plasma Cytokine Levels
Plasma samples were obtained after speed centrifuga-
tion for 10 minutes at 2000 rpm and immediately aliquoted
and stored at 280°C. Plasma samples were assayed using the
multiplex bead–based assays Bio-Plex Pro Human group I 19
plex [interleukin (IL)-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-12, IL-13, IL-17, granulocyte colony stimulating
factor, GM-CSF, Interferon (IFN)-g, Monocyte Chemoattrac-
tant Protein 1 (MCP-1), macrophage inflammatory protein
1-b, Regulated on Activation, Normal T cell Expressed and
Secreted (RANTES), and tumor necrosis factor-a] and Bio-
Plex Pro Human group II cytokines (21 plex, BioRad
Laboratories). Plates were measured using the Bio-Plex
MagPix System and analyzed with the Bio-Plex Manager
version 6.0 (BioRad Laboratories).
Statistical Analysis
GraphPad Prism version 4.00 for Windows (GraphPad
Software) was used to perform statistical analyses. The
nonparametric Mann–Whitney/Wilcoxon tests were used to
compare continuous variables. Correlations were evaluated
with the nonparametric Spearman test. A P value ,0.05 was
considered statistically significant.
RESULTS
Gr-MDSC Expansion During PHI
We compared MDSC levels during PHI, CHI, and in HD
by flow cytometry. MDSC were identified as CD3- CD19-
CD56- (Lin2) HLA-DRlow/2 CD11b+ CD33+ (Fig. 1A);
monocytic and granulocytic subsets were evaluated by testing
the expression of CD14 and CD15, respectively. The expres-
sion of IL-4 receptor (CD124) was also analyzed. Gr-MDSC
(Lin2 HLA-DRlow/2 CD11b+ CD33+ CD142 CD15+ CD124+)
frequency was higher in patients with PHI compared with HD
(Fig. 1B), but an even higher level of Gr-MDSC was found in
patients with CHI (Fig. 1B). To evaluate whether the identified
Gr-MDSC were immature/promyelocitic MDSC, we tested the
expression of CD16. We found that Gr-MDSC expressed CD16
(Fig. 1A) indicating that the identified subset was not immature/
promyelocitic MDSC. In contrast, no expansion of the M-MDSC
subset (Lin2 HLA-DRlow/2 CD11b+ CD33+ CD14+ CD152
CD124+) was observed in all patient groups (Fig. 1A).
It has been described that MDSC expansion correlates
with CD38 expression on CD8 T cells from HIV+ pa-
tients.20,21 We did not find any correlation between the
frequency of CD38+ CD8+ T cells and Gr-MDSC in both
patients with PHI and CHI (data not shown), suggesting that
in PHI, Gr-MDSC expansion is not driven by CD8 T-cell
activation. Interestingly, no correlation was observed between
Gr-MDSC frequency and HIV viral load or CD4+ T-cell
count in both PHI and CHI (data not shown).
Until now, data on the kinetics of MDSC expansion
during PHI are lacking. To explore this issue, we grouped
patients with PHI according to Fiebig stages, and the MDSC
level was evaluated. A higher frequency of Gr-MDSC was
observed in Fiebig stages II/III compared with HD (Fig. 1C),
indicating that MDSC plays a role soon after infection.
Furthermore, the Gr-MDSC level was stably high in all the
other stages but in stage V, where it was comparable to HD
(Fig. 1C). No significant differences in MDSC frequency
were detected among Fiebig stages.
We evaluated whether Gr-MDSC from PHI are able to
suppress T-cell function. We found that, when cultured with
purified Gr-MDSC, PBMC from HD decreased their prolifera-
tion capability in response to anti-CD3/CD28 (Fig. 2A),
indicating the suppressive function of these cells. Moreover, in
PHI, we found an inverse correlation between Gr-MDSC
frequency and the capacity of CD8 T cells to produce IFN-g
when stimulated with HIV peptides (Figs. 2B, C), confirming
that this population is able to modulate T-cell function.
Plasmatic TRAIL Correlates With
Gr-MDSC Frequency
To evaluate the possible role of soluble mediators in
modulating Gr-MDSC frequency during HIV infection, the level
of 40 different cytokines and growth factors was analyzed in
plasma samples from PHI and CHI. Interestingly, a significant
correlation between tumor necrosis factor–related apoptosis-
inducing ligand (TRAIL) and Gr-MDSC frequency was found,
both in PHI and in CHI (Table 2, Supplemental Digital Content,
http://links.lww.com/QAI/A964). Unexpectedly, this correlation
was inverse in PHI and direct in CHI. Moreover, in CHI, the Gr-
MDSC frequency was positively correlated with several medi-
ators [GM-CSF, IL-3, IL-2Ra, IL-12p40, IL-16, Chemokine
(C-C motif) ligand 27 (CCL27), IFN-a, and MCP-1; Table 2,
Supplemental Digital Content, http://links.lww.com/QAI/A964],
suggesting a possible contribution of inflammation in driving
Gr-MDSC expansion during the chronic phase of HIV infection.
We then questioned whether TRAIL, GM-CSF, IL-3,
IL-2Ra, IL-12p40, IL-16, CCL27, IFN-a, and MCP-1 levels
were differently expressed in PHI and CHI. We found that
TRAIL was higher in PHI and CHI than that in HD, but no
difference between PHI and CHI was observed (Fig. 3A).
Moreover, TRAIL was highly expressed in the plasma of
patients with PHI in the early phases of infection (Fiebig II/III
and IV) compared with that of HD, and no difference was
detected among Fiebig stages (Fig. 3B).
We also found that the unique cytokine differently
expressed in PHI and CHI was GM-CSF, which was higher
in CHI than in PHI (Fig. 3C), while the other factors
were comparable (Table 2, Supplemental Digital Content,
http://links.lww.com/QAI/A964).
GM-CSF Makes Gr-MDSC From PHI Resistant
to TRAIL-Induced Apoptosis
TRAIL is a member of the tumor necrosis factor
superfamily, closely related to Fas ligand, and it is able to
induce apoptosis in several cell types,24 including MDSC.25 It
has been clearly demonstrated that GM-CSF is a pivotal factor
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in the modulation of MDSC frequency.8 Thus, we wondered
whether GM-CSF may explain the opposite correlation
between TRAIL and Gr-MDSC frequency in PHI and CHI
by modulating Gr-MDSC apoptosis. To this aim, we cultured
PBMC from PHI and CHI with r-TRAIL and the induction of
apoptosis of Gr-MDSC was evaluated by the expression of
Annexin V. As previously described,25 a high level of Gr-
MDSC cell death (Annexin V+) was observed after in vitro
culture. However, treatment with r-TRAIL was able to increase
the expression of Annexin V on the membrane of Gr-MDSC
from PHI but not from CHI (Fig. 4A, B), suggesting that
TRAIL differently affects Gr-MDSC from PHI and CHI. When
we treated PBMC from PHI and CHI with GM-CSF and
r-TRAIL, the TRAIL-induced apoptosis was abrogated in PHI
(Fig. 4A and B). We could not observe significant effects on
Gr-MDSC from CHI. However, GM-CSF in vitro treatment
decreased the basal Annexin V expression on Gr-MDSC from
both PHI and CHI (even if in CHI the difference was not
statistically significant).
DISCUSSION
With the increasing number of HIV-1 studies focusing
on HIV-1–associated persistent immune activation on the
course of HIV disease, the role of immunoregulatory cell
populations becomes more and more important. The immu-
nosuppressive ability of MDSC may be beneficial in curbing
the damaging effects of persistent immune activation and
consequent systemic inflammation associated with chronic
HIV-1 infection. However, the results from previous studies
showed also a possible deleterious effect of MDSC, as they
inhibit HIV-1–induced proliferation of CD8 T cells. To our
FIGURE 1. MDSC frequency during primary HIV infection. A, Gating strategy used to identify MDSC: in the morphological gate
(FSC/SSC) we excluded debris, then we gated Lin2/HLA-DRlow/2 cells. In this gate, we selected CD11b+CD33+ cells (MDSC). The
expression of CD14, CD15, CD16, and CD124 is shown on cells selected from the CD11b+CD33+ gate. The expression of CD124,
with its correspondent fluorescence minus one control (FMO), is shown as histogram. B, Gr-MDSC frequency in HD (16), PHI (51),
and CHI (26). C, Gr-MDSC frequency in PHI grouped after the Fiebig classification, and CHI. Results are shown as box and
whiskers. The Mann–Whitney test was applied, and P , 0.05 was considered significant.
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knowledge, no information about the kinetics of MDSC
expansion from acute to CHI is available. The present work
demonstrates for the first time that Gr-MDSC are already
expanded during PHI compared with healthy donors and have
suppressive activity, suggesting that this cell dynamics occurs
very early during HIV infection. In particular, Gr-MDSC
expansion was already observed in the first weeks after
infection (Fiebig stages II/III) and remained high over time.
To date, the driving force for Gr-MDSC expansion
during HIV infection has not been elucidated. In our study,
we did not find any correlation between Gr-MDSC and HIV
viral load during the acute phases of infection, suggesting that
HIV particles may not directly be involved in expanding
MDSC. Furthermore, we could not find correlations between
Gr-MDSC frequency and T-cell activation or inflammatory
factors, indicating that immune activation is not the major
FIGURE 3. TRAIL and GM-CSF plasma
level. A, Comparison of TRAIL plasma
level in HD (10), PHI (32), and CHI
(13). B, Evaluation of TRAIL plasma
level in 10 HD, 32 PHI grouped in
Fiebig II/III (9), Fiebig IV (6), Fiebig V
(7), Fiebig VI (10), and CHI (13). C,
GM-CSF plasma level (pg/mL) in HD
(10), PHI (32), and CHI (13). Results
are shown as box and whiskers. The
Mann–Whitney test was applied, and
P , 0.05 was considered significant.
FIGURE 2. Gr-MDSC from PHI in-
hibits T-cell activation. A, Proliferation
rate of stimulated PBMC from HD in
the presence of Gr-MDSC from PHI,
evaluated by flow cytometry. Repre-
sentative histogram of 3 independent
experiments is shown. B, IFN-g pro-
duction by CD8 T cells stimulated with
HIV-specific peptides from 2 repre-
sentative PHI. C, Correlation between
Gr-MDSC frequency and the percent-
age of CD8 T cells producing IFN-g
(evaluated by flow cytometry) from 16
PHI was evaluated by the Spearman
test. The P , 0.05 was considered
statistically significant.
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player in regulating MDSC frequency. Differently, in CHI,
the immune activation probably contributes to maintaining
MDSC. Although Gr-MDSC frequency is not correlated with
the expression of CD38 on T cells, the association with
soluble IL-2R alpha (clearly associated with T-cell activation
in patients infected with HIV26) suggests a correlation with
T-cell activation. The correlations with the other inflammatory
factors also suggest that the activation of different cell types
of the innate and adaptive immune system may play a role in
modulating Gr-MDSC in CHI.
Whether MDSC may have different roles during
acute and CHI has not yet been explored. It has been
suggested that MDSC functions may depend on the context
in which they expand: Brudecki et al27 showed, in a murine
model of sepsis, that MDSC can enhance or suppress
severe inflammation in early and late sepsis, respectively.
As such, it is important to further define the multifactorial
immunoregulatory network in HIV-1 infection. As stated
above, our data indicate that, unlike CHI, Gr-MDSC
frequency from PHI is not associated with proinflammatory
or anti-inflammatory plasma cytokines; however, they are
inversely correlated with TRAIL level. Interestingly,
a direct correlation was found in CHI. These data suggest
a different role of TRAIL during acute and chronic
infection: in PHI, TRAIL is able to induce apoptosis in
Gr-MDSC, whereas in CHI it is not, probably because of
the presence of other cytokines contributing to MDSC
survival. In particular, GM-CSF present in CHI and not in
FIGURE 4. GM-CSF and TRAIL effects on Gr-MDSC viability. Percentage of Gr-MDSC from PHI and CHI expressing Annexin V after
in vitro treatment with r-TRAIL and GM-CSF was evaluated by flow cytometry. A, Representative dot plots showing Annexin V
expression on gated Gr-MDSC (gating strategies in Fig. 1) from one patient with PHI and one patient with CHI. B, Annexin V
expression on Gr-MDSC from 8 PHI (2 Fiebig II/III, 1 Fiebig IV, 2 Fiebig V, and 3 Fiebig VI) and 8 CHI. Results are shown as box and
whiskers. The Wilcoxon test was applied, and P , 0.05 was considered significant. CTR, control condition.
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PHI may play a role in this context. In fact, it has been
demonstrated that MDSC expansion is regulated by several
soluble factors such as GM-CSF, granulocyte colony
stimulating factor, macrophage colony-stimulating factor,
IL-6, and others.28 Herein, our in vitro experiments suggest
that GM-CSF treatment of Gr-MDSC from PHI makes
these cells resistant to spontaneous and TRAIL-induced
apoptosis. The effect is less significant on Gr-MDSC from
CHI probably because of the presence of GM-CSF in vivo.
The role of recombinant TRAIL on Gr-MDSC survival was
clearly demonstrated25; however, contrary to the prevailing
view that “death receptor” engagement is invariably
proapoptotic, accumulated evidence suggests that death
receptors frequently initiate potent prosurvival signals,
some of which are cytokine/chemokine mediated (reviewed
in29). Because of the opposite correlations between Gr-
MDSC and TRAIL level in PHI and CHI, we may speculate
that during acute HIV infection, when GM-CSF is very
low, the expanded Gr-MDSC are susceptible to TRAIL-
induced apoptosis. On the contrary, during CHI, the
presence of GM-CSF not only counteracts the proapoptotic
function of TRAIL but also transforms it into a survival
factor for Gr-MDSC. This hypothesis is in agreement with
the data showing a higher frequency of Gr-MDSC in CHI
than that in PHI, and the direct correlation between TRAIL
and Gr-MDSC in CHI.
As we did not find any correlation between MDSC
frequency and viral load, or CD4+ T-cell count, it would be
very interesting to understand whether MDSC expansion may
revert after successful antiretroviral therapy, possibly by
modulating cytokines levels.
The identification of specific pathways able to induce
Gr-MDSC, or interactions between these immunoregulatory
cells and other components of the immune system, is pivotal
not only to understand the actual role of MDSC during HIV
infection but also to design highly effective HIV-1 treatment
and immune-based strategies. In fact, it has been demon-
strated that simian immunodeficiency virus vaccine–induced
MDSC inhibit protective cellular immunity in a nonhuman
primate model.30 Moreover, the frequency of MDSC is
markedly elevated in patients infected with HIV-1 receiving
a dendritic cell–based HIV-1 vaccine.31 It has been demon-
strated that MDSC are able to crosstalk with different cell
types of innate immune system, such as dendritic cells,
macrophages, and natural killer cells,32–34 which play a central
role in controlling microbes and in activating adaptive
immune response. To understand whether MDSC are
involved in the deregulation of these cells during HIV
infection is mandatory.
In conclusion, we found that Gr-MDSC are expanded
during the very first stages of PHI, indicating that this cell
population may play a relevant role in modulating the
immune response soon after virus acquisition. Importantly,
TRAIL may play a role in controlling Gr-MDSC expan-
sion. Further studies are mandatory to elucidate the
mechanisms modulating frequency and functions of MDSC
during the diverse phases of HIV infection with the
aim to identify future immune-based treatment and vaccination
strategies.
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